View Post

PreludeDx Present Results from PREDICT Study at ASBrS Annual Meeting

In Clinical Trials by Barbara Jacoby

Source: Prelude Corporation From: Prelude Corporation (PreludeDx), a leader in molecular diagnostics and personalized medicine for early stage breast cancer, presented interim results from its large PREDICT study during a poster presentation (Abstract ID: 581643), titled “Interim Analysis of the DCISionRT PREDICT Study: Clinical Utility of a Biologic Signature Predictive of Radiation Therapy (RT) Benefit in Patients with DCIS”, …